Table 1

Demographics and baseline characteristics (safety analysis set)

PlaceboSemaglutideLiraglutide
0.1 mg0.2 mg0.4 mg0.8 mg0.8 mg E1.6 mg E1.2 mg1.8 mg
Exposed patients, n464743484243474550
Diet and exercise/metformin, %22/7823/7714/8623/7719/8116/8419/8118/8224/76
Age, years55.3 ± 10.655.2 ± 10.154.7 ± 10.053.8 ± 10.255.0 ± 9.755.9 ± 7.956.4 ± 10.554.8 ± 9.254.3 ± 10.1
Women/men, %39/6134/6630/7023/7748/5237/6345/5531/6930/70
Diabetes duration, years2.4 ± 3.33.6 ± 5.02.3 ± 2.72.0 ± 2.33.0 ± 3.02.6 ± 2.11.8 ± 2.03.3 ± 3.42.5 ± 2.6
HbA1c, % (mmol/mol)8.1 ± 0.8 (65)8.2 ± 0.9 (66)8.2 ± 0.9 (66)8.1 ± 0.9 (65)8.2 ± 0.9 (66)8.0 ± 0.8 (64)8.0 ± 0.7 (64)8.0 ± 0.8 (64)8.1 ± 0.7 (65)
FPG, mmol/L8.9 ± 1.59.8 ± 2.79.5 ± 2.59.3 ± 2.19.5 ± 2.49.6 ± 2.19.0 ± 1.99.0 ± 2.39.3 ± 2.0
Body weight, kg90.5 ± 13.089.5 ± 14.286.3 ± 15.187.0 ± 14.085.9 ± 15.185.7 ± 12.684.5 ± 14.090.5 ± 13.587.2 ± 13.1
BMI, kg/m231.7 ± 3.831.5 ± 4.630.4 ± 3.929.7 ± 4.530.7 ± 4.531.2 ± 4.230.9 ± 4.731.0 ± 4.630.9 ± 4.6
Waist circumference, cm106 ± 11106 ± 11104 ± 9105 ± 12101 ± 11104 ± 11103 ± 11106 ± 11102 ± 12
Hip circumference, cm111 ± 10111 ± 11107 ± 8106 ± 10107 ± 10108 ± 11108 ± 10110 ± 11106 ± 13
  • Data are reported as the mean ± SD, unless otherwise stated.